Your browser doesn't support javascript.
loading
Production and characterization of a chimeric protein targeting synuclein epitopes for immunotherapy against synucleinopathies.
Carreño-Campos, Christian; Govea-Alonso, Dania O; Villarreal, Maria Luisa; Caltempa, Anabel O; Gonzalez-Ortega, Omar; Rosales-Mendoza, Sergio.
Afiliação
  • Carreño-Campos C; Centro de Investigación en Biotecnología, Universidad Autónoma del Estado de Morelos, Morelos, Mexico.
  • Govea-Alonso DO; Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
  • Villarreal ML; Centro de Investigación en Biotecnología, Universidad Autónoma del Estado de Morelos, Morelos, Mexico.
  • Caltempa AO; Centro de Investigación en Biotecnología, Universidad Autónoma del Estado de Morelos, Morelos, Mexico.
  • Gonzalez-Ortega O; Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
  • Rosales-Mendoza S; Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
Biotechnol Prog ; 39(6): e3390, 2023.
Article em En | MEDLINE | ID: mdl-37702113
The aggregation and spread of alpha-synuclein (αSyn) is associated with several pathogenic pathways that lead to neurodegeneration and, ultimately, to synucleinopathies development. Hence, the establishment of a safe and effective disease-modifying therapy that limits or prevents the spread of toxic αSyn aggregation could lead to positive clinical outcomes. A rational vaccine design can be focused on the selection of specific epitopes able to induce the immune response desired, for example, antibodies able to mediate the clearance of αSyn aggregates without the induction of inflammatory responses. To develop a rapid system for the evaluation of a vaccine candidate against synucleinopathies, rLTB-Syn (an antigen based on three B cell epitopes from αSyn and the B subunit of the heat-labile Escherichia coli enterotoxin [LTB] as adjuvant/carrier) was produced using recombinant E. coli (Rosetta DE3) as the expression host. The bacterial version of rLTB-Syn was produced as soluble protein at yields up to 1.72 mg/g biomass. A method for the purification of rLTB-Syn (~18 kDa) was developed based on ion exchange chromatography, reaching purity >93% with a final concentration of 82.6 µg/mL. Furthermore, the purified soluble rLTB-Syn retained GM1 binding activity, suggesting proper folding and pentameric structure. The results from this study establish a fast and effective method to obtain rLTB-Syn, making it useful in the design of novel vaccine formulations targeting synucleinopathies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Toxinas Bacterianas / Vacinas / Proteínas de Escherichia coli / Sinucleinopatias Limite: Humans Idioma: En Revista: Biotechnol Prog Assunto da revista: BIOTECNOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: México

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Toxinas Bacterianas / Vacinas / Proteínas de Escherichia coli / Sinucleinopatias Limite: Humans Idioma: En Revista: Biotechnol Prog Assunto da revista: BIOTECNOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: México